Gamot’s Acquisition of Anjan Drug


AZB & Partners advised PAG Asia Capital HK Limited, while Desai & Diwanji advised Anjan Drug.

Gamot, an investment platform formed by private equity (PE) firm PAG along with PE funds CX Partners and Samara Capital, completed the acquisition of a controlling stake in Anjan Drug.

Anjan Drug Private Limited manufactures pharmaceutical ingredients. The Company supplies valproic acid, sodium valproate, divalproex sodium, magnesium valporate, and gabapentin products.

The AZB & Partners team was led by partners Ashwath Rau (Picture) and Atreya Bhattacharya, senior associate Raina Upadhyay.

The Desai & Diwanji team was led by partner Siddarth Modywith, senior associates Rahul Deodhar and Prerana Chaudhari.

Involved fees earner: Atreya Bhattacharya – Azb & partners; Ashwath Rau – Azb & partners; Raina Upadhyay – Azb & partners; Prerana Chaudhari – Desai & Diwanji; Rahul Deodhar – Desai & Diwanji; Siddharth Mody – Desai & Diwanji;

Law Firms: Azb & partners; Desai & Diwanji;

Clients: Anjan Drug ; PAG Asia Capital;

Author: Michael Patrini